• 1
    Merikangas KR, Akiskal HS, Angst J et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Arch Gen Psychiatry 2007;64:543552.
  • 2
    Gao K, Tolliver BK, Kemp DE et al. Differential interactions between comorbid anxiety disorders and substance use disorder in rapid cycling bipolar I or II disorder. J Affect Disord 2008;110:167173.
  • 3
    Goldstein BI, Fagiolini A, Houck P, Kupfer DJ. Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disord 2009;11:657662.
  • 4
    McIntyre RS, Konarski JZ, Soczynska JK et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr Serv 2006;57:11401144.
  • 5
    Kemp DE, Gao K, Ganocy SJ et al. Medical and substance use comorbidity in bipolar disorder. J Affect Disord 2009;116:6469.
  • 6
    Kupka RW, Nolen WA, Post RM et al. High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biol Psychiatry 2002;51:305311.
  • 7
    Matthews AM, Huckans MS, Blackwell AD, Hauser P. Hepatitis C testing and infection rates in bipolar patients with and without comorbid substance use disorders. Bipolar Disord 2008;10:266270.
  • 8
    Van Winkel R, De Hert M, Van Eyck D et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord 2008;10:342348.
  • 9
    Goldstein BI, Liu SM, Zivkovic N et al. The burden of obesity among adults with bipolar disorder in the United States. Bipolar Disord 2011;13:387395.
  • 10
    McElroy SL, Frye MA, Suppes T et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 2002;63:207213.
  • 11
    Centorrino F, Mark TL, Talamo A, Oh K, Chang J. Health and economic burden of metabolic comorbidity among individuals with bipolar disorder. J Clin Psychopharmacol 2009;29:595600.
  • 12
    Kemp DE, Gao K, Chan PK et al. Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome. Bipolar Disord 2010;12:404413.
  • 13
    Kilbourne AM, Perron BE, Mezuk B et al. Co-occurring conditions and health-related quality of life in patients with bipolar disorder. Psychosom Med 2009;71:894900.
  • 14
    Fagiolini A, Goracci A. The effects of undertreated chronic medical illnesses in patients with severe mental disorders. J Clin Psychiatry 2009;70(Suppl 3):2229.
  • 15
    Kilbourne AM, Rofey DL, McCarthy JF et al. Nutrition and exercise behavior among patients with bipolar disorder. Bipolar Disord 2007;9:443452.
  • 16
    Thompson WK, Kupfer DJ, Fagiolini A, Scott JA, Frank E. Prevalence and clinical correlates of medical comorbidities in patients with bipolar I disorder: analysis of acute-phase data from a randomized controlled trial. J Clin Psychiatry 2006;67:783788.
  • 17
    Vogelzangs N, Kritchevsky SB, Beekman AT et al. Obesity and onset of significant depressive symptoms: results from a prospective community-based cohort study of older men and women. J Clin Psychiatry 2010;71:391399.
  • 18
    Van Reedt Dortland AK, Giltay EJ, Van Veen T et al. Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use. Acta Psychiatr Scand 2010;122:3039.
  • 19
    Ortiz A,Cervantes P, Zlotnik GCross-prevalence of migraine and bipolar disorder. Bipolar Disord 2010;12:397403.
  • 20
    Gildengers AG, Whyte EM, Drayer RA et al. Medical burden in late-life bipolar and major depressive disorders. Am J Geriatr Psychiatry 2008;16:194200.
  • 21
    Perron BE, Howard MO, Nienhuis JK et al. Prevalence and burden of general medical conditions among adults with bipolar I disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2009;70:14071415.
  • 22
    Nierenberg AA, Sylvia LG, Leon AC et al. Lithium treatment – moderate dose use study (LiTMUS) for bipolar disorder: rationale and design. Clin Trials 2009;6:637648.
  • 23
    Sylvia LG, Reilly-Harrington NA, Leon AC et al. Methods to limit attrition in longitudinal comparative effectiveness trials: lessons from the Lithium Treatment - Moderate dose Use Study (LiTMUS) for bipolar disorder. Clin Trials 2012;9:94101.
  • 24
    Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997;73:159171.
  • 25
    Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl 20):2233.
  • 26
    First MB, Spitzer RL, Gibbon M, Williams JBW, Benjamin LS. Structured clinical interview for DSM-IV axis I disorders, patient version. Washington, DC: American Psychiatric Press, 1997.
  • 27
    Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382389.
  • 28
    Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429435.
  • 29
    Trivedi MH, Rush AJ, Ibrahim al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 2004;34:7382.
  • 30
    Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull 1993;29:321326.
  • 31
    Leon AC, Solomon DA, Mueller TI et al. A brief assessment of psychosocial functioning of subjects with bipolar I disorder: the LIFE-RIFT. Longitudinal interval follow-up evaluation-range impaired functioning tool. J Nerv Ment Dis 2000;188:805812.
  • 32
    Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 1968;16:622626.
  • 33
    Conwell Y, Forbes NT, Cox C, Caine ED. Validation of a measure of physical illness burden at autopsy: the cumulative illness rating scale. J Am Geriatr Soc 1993;41:3841.
  • 34
    Papakostas GI, Petersen T, Iosifescu DV et al. Axis III disorders in treatment-resistant major depressive disorder. Psychiatry Res 2003;118:183188.
  • 35
    Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:24862497.
  • 36
    Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, Miller DD, Haynes WG. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann Clin Psychiatry 2008;20:131137.
  • 37
    Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2004;61:11071115.
  • 38
    Malhi GS, Berk M. Is the safety of lithium no longer in the balance? Lancet 2012;379:690692.
  • 39
    Tredget J, Kirov A, Kirov G. Effects of chronic lithium treatment on renal function. J Affect Disord 2010;126:436440.
  • 40
    Soreca I, Fagiolini A, Frank E et al. Relationship of general medical burden, duration of illness and age in patients with bipolar I disorder. J Psychiatr Res 2008;42:956961.
  • 41
    Yates WR, Mitchell J, John Rush A et al. Clinical features of depression in outpatients with and without co-occurring general medical conditions in STAR*D: confirmatory analysis. Prim Care Companion J Clin Psychiatry 2007;9:715.
  • 42
    Gili M, Garcia-Toro M, Vives M et al. Medical comorbidity in recurrent versus first-episode depressive patients. Acta Psychiatr Scand 2011;123:220227.
  • 43
    Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA 2010;303:235241.
  • 44
    McEvoy JP, Meyer JM, Goff DC et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:1932.
  • 45
    Kemp DE, Karayal ON, Calabrese JR et al. Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles. Eur Neuropsychopharmacol 2012;22:123131.
  • 46
    Fernandez JR, Heo M, Heymsfield SB et al. Is percentage body fat differentially related to body mass index in Hispanic Americans, African Americans, and European Americans? Am J Clin Nutr 2003;77:7175.
  • 47
    Sanchez-Moreno J, Martinez-Aran A, Tabares-Seisdedos R et al. Functioning and disability in bipolar disorder: an extensive review. Psychother Psychosom 2009;78:285297.
  • 48
    Lindenmayer JP, Khan A, Kaushik S et al. Relationship between metabolic syndrome and cognition in patients with schizophrenia. Schizophr Res 2012;142:171176.
  • 49
    Leucht S, Burkard T, Henderson J et al. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007;116:317333.